Articles from Hummingbird Diagnostics

Hummingbird Diagnostics GmbH, a pioneer in blood-based small RNA biomarker discovery and assay development, today announced new clinical data demonstrating the ability of small RNA to enable adaptive treatment strategies in lung cancer patients. The results were presented at the ESMO Congress 2026 in Madrid, Spain.

Hummingbird Diagnostics GmbH, a molecular diagnostics company specializing in blood-based small RNA analysis for precision oncology, today announced that data from a new collaborative study will be presented at the ESMO Congress 2026 in Madrid, Spain.

Hummingbird Diagnostics GmbH, a pioneer in leveraging blood-based small RNA diagnostics for early cancer detection and characterization with an initial focus on lung cancer, today announced the appointment of Vince Lozada as its new Chief Executive Officer as the company enters its next phase of product evolution and innovation. Vince brings more than 20 years of experience in the life sciences and technology industries, spanning R&D, finance, and business development. His background in early cancer detection aligns with Hummingbird’s mission to improve the precision, informativeness, and accessibility of blood-based cancer diagnostics.